Light Horse Therapeutics Partners with Novartis to Discover Therapies for Cancer Treatment
Shots:
- Light Horse has entered into a multi-target partnership with Novartis to discover & develop FIC targets for cancer treatment by using its proprietary chemical libraries & precision genetic editing platform that identifies novel functional domains in disease-critical targets
- As per the agreement, Light Horse is entitled to receive $25M upfront, $1B research, development & sales milestones plus royalties on licensed therapeutics. Further terms are not disclosed
- In addition, the company has secured $62M in Series A funding led by Versant Ventures, with Mubadala Capital, BMS, Taiho Ventures & AbbVie
Ref: Businesswire | Image: Novartis & Light Horse
Related News:- PTC Therapeutics Join Forces with Novartis to Develop PTC518 for Treating Huntington's Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
